Ascentage Pharma AAPG
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$33.7K (3 inflow days, 17 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 23.7% of shares outstanding.
Largest holders
By investor type
Reported short interest has held roughly steady near 0.01% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Ping An of China Asset Management (Hong Kong) Company Limited | Mutual Fund | 2026/Q3 | +1,407 | 0.0% |
| China Asset Management Co., Ltd. | Mutual Fund | 2026/Q3 | +28,510 | 0.5% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +49,000 | 0.2% |
| China Asset Management (Hong Kong) Limited | Mutual Fund | 2026/Q3 | +209,550 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +16,950 | 1.5% |
| China Asset Management Co., Ltd. | Mutual Fund | 2026/Q3 | +56,585 | 0.5% |
| CSOP Asset Management Limited | Mutual Fund | 2026/Q3 | +1,569 | 0.1% |
| HSBC Global Asset Management (UK) Limited | Mutual Fund | 2026/Q3 | +5,048 | 0.0% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +217,150 | 3.4% |
| China Asset Management (Hong Kong) Limited | Mutual Fund | 2026/Q3 | +208,900 | 0.2% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +49,900 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +15,625 | 1.5% |
| Arax Advisory Partners, LLC | Mutual Fund | 2026/Q3 | +1,230 | 0.0% |
| China Asset Management Co., Ltd. | Mutual Fund | 2026/Q3 | +5,280 | 0.5% |
| CSOP Asset Management Limited | Mutual Fund | 2026/Q3 | +234 | 0.1% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 20 May 2026 | Yifan Zhai | Chief Medical Officer | Derivative Exercise and Retained | +92,746 | – | 405,280 |
| 20 May 2026 | Dajun Yang | Chairperson & CEO | Derivative Exercise and Retained | +95,575 | – | 23,247,700 |
| 19 May 2026 | Yifan Zhai | Chief Medical Officer | Other Derivative Acquisition | +616,546 | $8.12 | 298,194 |
| 19 May 2026 | Yifan Zhai | Chief Medical Officer | Other Derivative Acquisition | +804,880 | – | 298,195 |
| 19 May 2026 | Dajun Yang | Chairperson & CEO | Other Derivative Acquisition | +616,546 | $8.12 | 103,364 |
| 19 May 2026 | Dajun Yang | Chairperson & CEO | Other Derivative Acquisition | +804,880 | – | 92,746 |
| 17 Mar 2026 | Jiuyun Yu | Independent Non-Executive Director | Initial Statement of Beneficial | +0 | – | 27,965 |
| 17 Mar 2026 | Marc Lippman | Independent Non-Executive Director | Initial Statement of Beneficial | +0 | – | 21,174 |
| 17 Mar 2026 | Marina S. Bozilenko | Independent Non-Executive Director | Initial Statement of Beneficial | +0 | – | 45,930 |
| 17 Mar 2026 | David Sidransky | Lead Independent Non-Executive Director | Initial Statement of Beneficial | +0 | – | 10,641 |
| 17 Mar 2026 | Thomas Knapp | General Counsel | Initial Statement of Beneficial | +0 | – | 38,938 |
| 17 Mar 2026 | Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | Initial Statement of Beneficial | +0 | – | 27,965 |
| 17 Mar 2026 | Yifan Zhai | Chief Medical Officer | Initial Statement of Beneficial | +0 | – | 103,364 |
| 17 Mar 2026 | Changqing Ye | Independent Non-Executive Director | Initial Statement of Beneficial | +0 | – | 8,964 |
| 17 Mar 2026 | Dazhong Lu | Independent Non-Executive Director | Initial Statement of Beneficial | +0 | – | 41,457 |
| 17 Mar 2026 | HealthQuest Pharma Limited | Initial Statement of Beneficial | +0 | – | 14,089,111 | |
| 17 Mar 2026 | Dajun Yang | Chairperson & CEO | Initial Statement of Beneficial | +0 | – | 143,463 |
| 17 Mar 2026 | Wei Ren | Independent Non-Executive Director | Initial Statement of Beneficial | +0 | – | 28,850 |
| 17 Mar 2026 | Jin Cao | Head of Finance | Initial Statement of Beneficial | +0 | – | 12,883 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 9,125 | 0.0% | 1.0 |
| 15 Oct 2026 | 18,161 | 0.0% | 2.6 |
| 30 Sep 2026 | 9,250 | 0.0% | 1.5 |
| 15 Sep 2026 | 19,861 | 0.0% | 3.1 |
| 31 Aug 2026 | 15,260 | 0.0% | 1.8 |
| 14 Aug 2026 | 14,177 | 0.0% | 2.9 |
No comments yet — be the first to weigh in on AAPG.
Sign in to join the discussion.